{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:26:23Z","timestamp":1790803583079,"version":"4.1.0"},"reference-count":154,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Endocrinol"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1038\/s41574-026-01271-8","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T16:02:54Z","timestamp":1781798574000},"page":"602-614","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["From bench to bedside: the evolving role of iodine in thyroid cancer management"],"prefix":"10.1038","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4569-5398","authenticated-orcid":false,"given":"Vincenzo","family":"Condello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim N.","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Zedenius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5945-9081","authenticated-orcid":false,"given":"C. Christofer","family":"Juhlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"key":"1271_CR1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s12022-022-09707-3","volume":"33","author":"ZW Baloch","year":"2022","unstructured":"Baloch, Z. W. et al. Overview of the 2022 WHO classification of thyroid neoplasms. Endocr. Pathol. 33, 27\u201363 (2022).","journal-title":"Endocr. Pathol."},{"key":"1271_CR2","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1210\/jc.2014-3882","volume":"100","author":"L Lamartina","year":"2015","unstructured":"Lamartina, L., Durante, C., Filetti, S. & Cooper, D. S. Low-risk differentiated thyroid cancer and radioiodine remnant ablation: a systematic review of the literature. J. Clin. Endocrinol. Metab. 100, 1748\u20131761 (2015).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1271_CR3","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/s00259-019-04479-1","volume":"47","author":"FA Verburg","year":"2020","unstructured":"Verburg, F. A. et al. Differentiated thyroid cancer patients potentially benefitting from postoperative I-131 therapy: a review of the literature of the past decade. Eur. J. Nucl. Med. Mol. Imaging 47, 78\u201383 (2020).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1271_CR4","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1177\/10507256251363120","volume":"35","author":"MD Ringel","year":"2025","unstructured":"Ringel, M. D. et al. 2025 American Thyroid Association management guidelines for adult patients with differentiated thyroid cancer. Thyroid 35, 841\u2013985 (2025).","journal-title":"Thyroid"},{"key":"1271_CR5","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1056\/NEJMoa2111953","volume":"386","author":"S Leboulleux","year":"2022","unstructured":"Leboulleux, S. et al. Thyroidectomy without radioiodine in patients with low-risk thyroid cancer. N. Engl. J. Med. 386, 923\u2013932 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1271_CR6","first-page":"1551","volume":"39","author":"C Alexander","year":"1998","unstructured":"Alexander, C., Bader, J. B., Schaefer, A., Finke, C. & Kirsch, C. M. Intermediate and long-term side effects of high-dose radioiodine therapy for thyroid carcinoma. J. Nucl. Med. 39, 1551\u20131554 (1998).","journal-title":"J. Nucl. Med."},{"key":"1271_CR7","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1210\/jc.2005-2838","volume":"91","author":"C Durante","year":"2006","unstructured":"Durante, C. et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J. Clin. Endocrinol. Metab. 91, 2892\u20132899 (2006).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1271_CR8","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1089\/thy.2018.0597","volume":"29","author":"RM Tuttle","year":"2019","unstructured":"Tuttle, R. M. et al. Controversies, consensus, and collaboration in the use of 131I therapy in differentiated thyroid cancer: a joint statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the European Thyroid Association. Thyroid 29, 461\u2013470 (2019).","journal-title":"Thyroid"},{"key":"1271_CR9","doi-asserted-by":"publisher","DOI":"10.1530\/ETJ-21-0046","volume":"11","author":"F Pacini","year":"2022","unstructured":"Pacini, F. et al. 2022 ETA consensus statement: what are the indications for post-surgical radioiodine therapy in differentiated thyroid cancer? Eur. Thyroid J. 11, e210046 (2022).","journal-title":"Eur. Thyroid J."},{"key":"1271_CR10","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1146\/annurev-physiol-022516-034125","volume":"79","author":"S Ravera","year":"2017","unstructured":"Ravera, S., Reyna-Neyra, A., Ferrandino, G., Amzel, L. M. & Carrasco, N. The sodium\/iodide symporter (NIS): molecular physiology and preclinical and clinical applications. Annu. Rev. Physiol. 79, 261\u2013289 (2017).","journal-title":"Annu. Rev. Physiol."},{"key":"1271_CR11","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","volume":"384","author":"MS Brose","year":"2014","unstructured":"Brose, M. S. et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 384, 319\u2013328 (2014).","journal-title":"Lancet"},{"key":"1271_CR12","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1097\/CCO.0000000000000027","volume":"26","author":"M Giuliani","year":"2014","unstructured":"Giuliani, M. & Brierley, J. Indications for the use of external beam radiation in thyroid cancer. Curr. Opin. Oncol. 26, 45\u201350 (2014).","journal-title":"Curr. Opin. Oncol."},{"key":"1271_CR13","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1406470","volume":"372","author":"M Schlumberger","year":"2015","unstructured":"Schlumberger, M. et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N. Engl. J. Med. 372, 621\u2013630 (2015).","journal-title":"N. Engl. J. Med."},{"key":"1271_CR14","first-page":"R173","volume":"29","author":"M-C Hofmann","year":"2022","unstructured":"Hofmann, M.-C. et al. Molecular mechanisms of resistance to kinase inhibitors and redifferentiation in thyroid cancers. Endocr. Relat. Cancer 29, R173\u2013R190 (2022).","journal-title":"Endocr. Relat. Cancer"},{"key":"1271_CR15","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1056\/NEJMoa1209288","volume":"368","author":"AL Ho","year":"2013","unstructured":"Ho, A. L. et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N. Engl. J. Med. 368, 623\u2013632 (2013).","journal-title":"N. Engl. J. Med."},{"key":"1271_CR16","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1158\/1078-0432.CCR-23-0046","volume":"29","author":"S Leboulleux","year":"2023","unstructured":"Leboulleux, S. et al. A phase II redifferentiation trial with dabrafenib-trametinib and 131I in metastatic radioactive iodine refractory BRAF p.V600E-mutated differentiated thyroid cancer. Clin. Cancer Res. 29, 2401\u20132409 (2023).","journal-title":"Clin. Cancer Res."},{"key":"1271_CR17","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1586\/eem.10.40","volume":"5","author":"A Leung","year":"2010","unstructured":"Leung, A., Pearce, E. N. & Braverman, L. E. Role of iodine in thyroid physiology. Expert Rev. Endocrinol. Metab. 5, 593\u2013602 (2010).","journal-title":"Expert Rev. Endocrinol. Metab."},{"key":"1271_CR18","doi-asserted-by":"publisher","first-page":"4469","DOI":"10.3390\/nu13124469","volume":"13","author":"S Sorrenti","year":"2021","unstructured":"Sorrenti, S. et al. Iodine: its role in thyroid hormone biosynthesis and beyond. Nutrients 13, 4469 (2021).","journal-title":"Nutrients"},{"key":"1271_CR19","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/S0140-6736(83)90636-0","volume":"2","author":"BS Hetzel","year":"1983","unstructured":"Hetzel, B. S. Iodine deficiency disorders (IDD) and their eradication. Lancet 2, 1126\u20131129 (1983).","journal-title":"Lancet"},{"key":"1271_CR20","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/S0140-6736(08)61005-3","volume":"372","author":"MB Zimmermann","year":"2008","unstructured":"Zimmermann, M. B., Jooste, P. L. & Pandav, C. S. Iodine-deficiency disorders. Lancet 372, 1251\u20131262 (2008).","journal-title":"Lancet"},{"key":"1271_CR21","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1126\/science.218285","volume":"203","author":"JH Oppenheimer","year":"1979","unstructured":"Oppenheimer, J. H. Thyroid hormone action at the cellular level. Science 203, 971\u2013979 (1979).","journal-title":"Science"},{"key":"1271_CR22","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1210\/er.2009-0007","volume":"31","author":"S-Y Cheng","year":"2010","unstructured":"Cheng, S.-Y., Leonard, J. L. & Davis, P. J. Molecular aspects of thyroid hormone actions. Endocr. Rev. 31, 139\u2013170 (2010).","journal-title":"Endocr. Rev."},{"key":"1271_CR23","doi-asserted-by":"publisher","first-page":"111173","DOI":"10.1016\/j.mce.2021.111173","volume":"525","author":"U Feldt-Rasmussen","year":"2021","unstructured":"Feldt-Rasmussen, U., Effraimidis, G. & Klose, M. The hypothalamus\u2013pituitary\u2013thyroid (HPT)-axis and its role in physiology and pathophysiology of other hypothalamus\u2013pituitary functions. Mol. Cell Endocrinol. 525, 111173 (2021).","journal-title":"Mol. Cell Endocrinol."},{"key":"1271_CR24","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1111\/1440-1681.12887","volume":"45","author":"LPL Matos","year":"2018","unstructured":"Matos, L. P. L. et al. Regulation of thyroid sodium\u2013iodide symporter in different stages of goiter: possible involvement of reactive oxygen species. Clin. Exp. Pharmacol. Physiol. 45, 326\u2013334 (2018).","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"1271_CR25","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1038\/379458a0","volume":"379","author":"G Dai","year":"1996","unstructured":"Dai, G., Levy, O. & Carrasco, N. Cloning and characterization of the thyroid iodide transporter. Nature 379, 458\u2013460 (1996).","journal-title":"Nature"},{"key":"1271_CR26","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1006\/bbrc.1996.1358","volume":"226","author":"PA Smanik","year":"1996","unstructured":"Smanik, P. A. et al. Cloning of the human sodium lodide symporter. Biochem. Biophys. Res. Commun. 226, 339\u2013345 (1996).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"1271_CR27","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.pharmthera.2012.06.007","volume":"135","author":"T Kogai","year":"2012","unstructured":"Kogai, T. & Brent, G. A. The sodium iodide symporter (NIS): regulation and approaches to targeting for cancer therapeutics. Pharmacol. Ther. 135, 355\u2013370 (2012).","journal-title":"Pharmacol. Ther."},{"key":"1271_CR28","doi-asserted-by":"publisher","first-page":"6251","DOI":"10.7150\/thno.57689","volume":"11","author":"JM Oh","year":"2021","unstructured":"Oh, J. M. & Ahn, B.-C. Molecular mechanisms of radioactive iodine refractoriness in differentiated thyroid cancer: impaired sodium iodide symporter (NIS) expression owing to altered signaling pathway activity and intracellular localization of NIS. Theranostics 11, 6251\u20136277 (2021).","journal-title":"Theranostics"},{"key":"1271_CR29","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1038\/s41586-022-05530-2","volume":"612","author":"S Ravera","year":"2022","unstructured":"Ravera, S. et al. Structural insights into the mechanism of the sodium\/iodide symporter. Nature 612, 795\u2013801 (2022).","journal-title":"Nature"},{"key":"1271_CR30","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/ng0697-124","volume":"16","author":"H Fujiwara","year":"1997","unstructured":"Fujiwara, H. et al. Congenital hypothyroidism caused by a mutation in the Na+\/I\u2212 symporter. Nat. Genet. 16, 124\u2013125 (1997).","journal-title":"Nat. Genet."},{"key":"1271_CR31","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1089\/thy.2018.0137","volume":"28","author":"Y Watanabe","year":"2018","unstructured":"Watanabe, Y., Ebrhim, R. S., Abdullah, M. A. & Weiss, R. E. A novel missense mutation in the SLC5A5 gene in a Sudanese family with congenital hypothyroidism. Thyroid 28, 1068\u20131070 (2018).","journal-title":"Thyroid"},{"key":"1271_CR32","doi-asserted-by":"publisher","first-page":"K1","DOI":"10.1530\/EJE-20-0255","volume":"183","author":"A Stoupa","year":"2020","unstructured":"Stoupa, A. et al. First case of fetal goitrous hypothyroidism due to SLC5A5\/NIS mutations. Eur. J. Endocrinol. 183, K1\u2013K5 (2020).","journal-title":"Eur. J. Endocrinol."},{"key":"1271_CR33","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1046\/j.1365-2265.2002.01640.x","volume":"57","author":"C Spitzweg","year":"2002","unstructured":"Spitzweg, C. & Morris, J. C. The sodium iodide symporter: its pathophysiological and therapeutic implications. Clin. Endocrinol. 57, 559\u2013574 (2002).","journal-title":"Clin. Endocrinol."},{"key":"1271_CR34","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/7783","volume":"21","author":"DA Scott","year":"1999","unstructured":"Scott, D. A., Wang, R., Kreman, T. M., Sheffield, V. C. & Karniski, L. P. The Pendred syndrome gene encodes a chloride\u2013iodide transport protein. Nat. Genet. 21, 440\u2013443 (1999).","journal-title":"Nat. Genet."},{"key":"1271_CR35","doi-asserted-by":"publisher","first-page":"3356","DOI":"10.1210\/jcem.87.7.8679","volume":"87","author":"A Yoshida","year":"2002","unstructured":"Yoshida, A. et al. Pendrin is an iodide-specific apical porter responsible for iodide efflux from thyroid cells. J. Clin. Endocrinol. Metab. 87, 3356\u20133361 (2002).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1271_CR36","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1210\/endo.141.2.7303","volume":"141","author":"IE Royaux","year":"2000","unstructured":"Royaux, I. E. et al. Pendrin, the protein encoded by the Pendred syndrome gene (PDS), is an apical porter of iodide in the thyroid and is regulated by thyroglobulin in FRTL-5 cells. Endocrinology 141, 839\u2013845 (2000).","journal-title":"Endocrinology"},{"key":"1271_CR37","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.tem.2008.07.001","volume":"19","author":"P Kopp","year":"2008","unstructured":"Kopp, P., Pesce, L. & Solis-S, J. C. Pendred syndrome and iodide transport in the thyroid. Trends Endocrinol. Metab. 19, 260\u2013268 (2008).","journal-title":"Trends Endocrinol. Metab."},{"key":"1271_CR38","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/ng1297-411","volume":"17","author":"LA Everett","year":"1997","unstructured":"Everett, L. A. et al. Pendred syndrome is caused by mutations in a putative sulphate transporter gene (PDS). Nat. Genet. 17, 411\u2013422 (1997).","journal-title":"Nat. Genet."},{"key":"1271_CR39","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.2741\/4677","volume":"23","author":"S Benvenga","year":"2018","unstructured":"Benvenga, S. & Guarneri, F. Homology of pendrin, sodium\u2013iodide symporter and apical iodide transporter. Front. Biosci. 23, 1864\u20131873 (2018).","journal-title":"Front. Biosci."},{"key":"1271_CR40","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1210\/en.2005-1149","volume":"147","author":"M-F Van Den Hove","year":"2006","unstructured":"Van Den Hove, M.-F. et al. The loss of the chloride channel, ClC-5, delays apical iodide efflux and induces a euthyroid goiter in the mouse thyroid gland. Endocrinology 147, 1287\u20131296 (2006).","journal-title":"Endocrinology"},{"key":"1271_CR41","doi-asserted-by":"publisher","first-page":"5929","DOI":"10.1113\/jphysiol.2011.218594","volume":"589","author":"P Fong","year":"2011","unstructured":"Fong, P. Thyroid iodide efflux: a team effort? J. Physiol. 589, 5929\u20135939 (2011).","journal-title":"J. Physiol."},{"key":"1271_CR42","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1097\/MED.0000000000000188","volume":"22","author":"JC Silveira","year":"2015","unstructured":"Silveira, J. C. & Kopp, P. A. Pendrin and anoctamin as mediators of apical iodide efflux in thyroid cells. Curr. Opin. Endocrinol. Diabetes Obes. 22, 374\u2013380 (2015).","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"1271_CR43","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.abb.2005.06.023","volume":"445","author":"J Ruf","year":"2006","unstructured":"Ruf, J. & Carayon, P. Structural and functional aspects of thyroid peroxidase. Arch. Biochem. Biophys. 445, 269\u2013277 (2006).","journal-title":"Arch. Biochem. Biophys."},{"key":"1271_CR44","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.beem.2017.04.006","volume":"31","author":"M Muzza","year":"2017","unstructured":"Muzza, M. & Fugazzola, L. Disorders of H2O2 generation. Best Pract. Res. Clin. Endocrinol. Metab. 31, 225\u2013240 (2017).","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"1271_CR45","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00251-002-0453-9","volume":"54","author":"T Chard\u00e8s","year":"2002","unstructured":"Chard\u00e8s, T. et al. The human anti-thyroid peroxidase autoantibody repertoire in Graves\u2019 and Hashimoto\u2019s autoimmune thyroid diseases. Immunogenetics 54, 141\u2013157 (2002).","journal-title":"Immunogenetics"},{"key":"1271_CR46","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1172\/JCI115981","volume":"90","author":"MJ Abramowicz","year":"1992","unstructured":"Abramowicz, M. J. et al. Identification of a mutation in the coding sequence of the human thyroid peroxidase gene causing congenital goiter. J. Clin. Invest. 90, 1200\u20131204 (1992).","journal-title":"J. Clin. Invest."},{"key":"1271_CR47","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1159\/000324882","volume":"75","author":"HM Targovnik","year":"2011","unstructured":"Targovnik, H. M., Citterio, C. E. & Rivolta, C. M. Thyroglobulin gene mutations in congenital hypothyroidism. Horm. Res. Paediatr. 75, 311\u2013321 (2011).","journal-title":"Horm. Res. Paediatr."},{"key":"1271_CR48","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-24-0334","volume":"32","author":"GM Schmidt","year":"2025","unstructured":"Schmidt, G. M. et al. Spectrum and carcinogenic properties of thyroglobulin gene fusions in thyroid. Endocr. Relat. Cancer 32, e240334 (2025).","journal-title":"Endocr. Relat. Cancer"},{"key":"1271_CR49","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/s41574-019-0184-8","volume":"15","author":"CE Citterio","year":"2019","unstructured":"Citterio, C. E., Targovnik, H. M. & Arvan, P. The role of thyroglobulin in thyroid hormonogenesis. Nat. Rev. Endocrinol. 15, 323\u2013338 (2019).","journal-title":"Nat. Rev. Endocrinol."},{"key":"1271_CR50","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/ncpendmet0757","volume":"4","author":"CA Spencer","year":"2008","unstructured":"Spencer, C. A. & Lopresti, J. S. Measuring thyroglobulin and thyroglobulin autoantibody in patients with differentiated thyroid cancer. Nat. Clin. Pract. Endocrinol. Metab. 4, 223\u2013233 (2008).","journal-title":"Nat. Clin. Pract. Endocrinol. Metab."},{"key":"1271_CR51","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.beem.2007.03.009","volume":"21","author":"CE Schwartz","year":"2007","unstructured":"Schwartz, C. E. & Stevenson, R. E. The MCT8 thyroid hormone transporter and Allan\u2013Herndon\u2013Dudley syndrome. Best Pract. Res. Clin. Endocrinol. Metab. 21, 307\u2013321 (2007).","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"1271_CR52","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.3390\/cancers13143627","volume":"13","author":"JN Nilsson","year":"2021","unstructured":"Nilsson, J. N., Siikanen, J., Hedman, C., Juhlin, C. C. & Ihre Lundgren, C. Pre-therapeutic measurements of iodine avidity in papillary and poorly differentiated thyroid cancer reveal associations with thyroglobulin expression, histological variants and Ki-67 index. Cancers 13, 3627 (2021).","journal-title":"Cancers"},{"key":"1271_CR53","doi-asserted-by":"publisher","first-page":"215","DOI":"10.3803\/EnM.2019.34.3.215","volume":"34","author":"J Liu","year":"2019","unstructured":"Liu, J., Liu, Y., Lin, Y. & Liang, J. Radioactive iodine-refractory differentiated thyroid cancer and redifferentiation therapy. Endocrinol. Metab. 34, 215\u2013225 (2019).","journal-title":"Endocrinol. Metab."},{"key":"1271_CR54","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1530\/ERC-13-0399","volume":"21","author":"Z Zhang","year":"2014","unstructured":"Zhang, Z., Liu, D., Murugan, A. K., Liu, Z. & Xing, M. Histone deacetylation of NIS promoter underlies BRAFV600E-promoted NIS silencing in thyroid cancer. Endocr. Relat. Cancer 21, 161\u2013173 (2014).","journal-title":"Endocr. Relat. Cancer"},{"key":"1271_CR55","first-page":"2697","volume":"86","author":"O Doh\u00e1n","year":"2001","unstructured":"Doh\u00e1n, O., Baloch, Z., B\u00e1nr\u00e9vi, Z., Livolsi, V. & Carrasco, N. Rapid communication: predominant intracellular overexpression of the Na+\/I\u2212 symporter (NIS) in a large sampling of thyroid cancer cases. J. Clin. Endocrinol. Metab. 86, 2697\u20132700 (2001).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1271_CR56","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1089\/thy.2011.0311","volume":"22","author":"I Kollecker","year":"2012","unstructured":"Kollecker, I. et al. Subcellular distribution of the sodium iodide symporter in benign and malignant thyroid tissues. Thyroid 22, 529\u2013535 (2012).","journal-title":"Thyroid"},{"key":"1271_CR57","first-page":"4102","volume":"83","author":"B Caillou","year":"1998","unstructured":"Caillou, B. et al. Na+\/I\u2212 symporter distribution in human thyroid tissues: an immunohistochemical study. J. Clin. Endocrinol. Metab. 83, 4102\u20134106 (1998).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1271_CR58","doi-asserted-by":"publisher","DOI":"10.1530\/ETJ-23-0099","volume":"12","author":"JN Nilsson","year":"2023","unstructured":"Nilsson, J. N. et al. Iodine avidity in papillary and poorly differentiated thyroid cancer is predicted by immunohistochemical and molecular work-up. Eur. Thyroid. J. 12, e230099 (2023).","journal-title":"Eur. Thyroid. J."},{"key":"1271_CR59","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/S2213-8587(14)70051-8","volume":"2","author":"C Spitzweg","year":"2014","unstructured":"Spitzweg, C., Bible, K. C., Hofbauer, L. C. & Morris, J. C. Advanced radioiodine-refractory differentiated thyroid cancer: the sodium iodide symporter and other emerging therapeutic targets. Lancet Diabetes Endocrinol. 2, 830\u2013842 (2014).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1271_CR60","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1677\/erc.1.01119","volume":"13","author":"G Riesco-Eizaguirre","year":"2006","unstructured":"Riesco-Eizaguirre, G., Guti\u00e9rrez-Mart\u00ednez, P., Garc\u00eda-Cabezas, M. A., Nistal, M. & Santisteban, P. The oncogene BRAFV600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+\/I\u2212 targeting to the membrane. Endocr. Relat. Cancer 13, 257\u2013269 (2006).","journal-title":"Endocr. Relat. Cancer"},{"key":"1271_CR61","doi-asserted-by":"publisher","first-page":"4700","DOI":"10.1172\/JCI46382","volume":"121","author":"D Chakravarty","year":"2011","unstructured":"Chakravarty, D. et al. Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. J. Clin. Invest. 121, 4700\u20134711 (2011).","journal-title":"J. Clin. Invest."},{"key":"1271_CR62","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1158\/1078-0432.CCR-06-1753","volume":"13","author":"D Liu","year":"2007","unstructured":"Liu, D. et al. Suppression of BRAF\/MEK\/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant. Clin. Cancer Res. 13, 1341\u20131349 (2007).","journal-title":"Clin. Cancer Res."},{"key":"1271_CR63","first-page":"1747","volume":"11","author":"T Endo","year":"1997","unstructured":"Endo, T. et al. Thyroid transcription factor-1 activates the promoter activity of rat thyroid Na+\/I\u2212 symporter gene. Mol. Endocrinol. 11, 1747\u20131755 (1997).","journal-title":"Mol. Endocrinol."},{"key":"1271_CR64","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1128\/MCB.19.3.2051","volume":"19","author":"M Ohno","year":"1999","unstructured":"Ohno, M., Zannini, M., Levy, O., Carrasco, N. & di Lauro, R. The paired-domain transcription factor Pax8 binds to the upstream enhancer of the rat sodium\/iodide symporter gene and participates in both thyroid-specific and cyclic-AMP-dependent transcription. Mol. Cell Biol. 19, 2051\u20132060 (1999).","journal-title":"Mol. Cell Biol."},{"key":"1271_CR65","doi-asserted-by":"publisher","first-page":"T141","DOI":"10.1530\/ERC-21-0217","volume":"28","author":"G Riesco-Eizaguirre","year":"2021","unstructured":"Riesco-Eizaguirre, G., Santisteban, P. & De La Vieja, A. The complex regulation of NIS expression and activity in thyroid and extrathyroidal tissues. Endocr. Relat. Cancer 28, T141\u2013T165 (2021).","journal-title":"Endocr. Relat. Cancer"},{"key":"1271_CR66","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1089\/ars.2015.6616","volume":"26","author":"N Azouzi","year":"2017","unstructured":"Azouzi, N. et al. NADPH oxidase NOX4 is a critical mediator of BRAFV600E-induced downregulation of the sodium\/iodide symporter in papillary thyroid carcinomas. Antioxid. Redox Signal. 26, 864\u2013877 (2017).","journal-title":"Antioxid. Redox Signal."},{"key":"1271_CR67","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s12022-025-09849-0","volume":"36","author":"V Condello","year":"2025","unstructured":"Condello, V., Marchettini, C., Ihre-Lundgren, C., Nilsson, J. N. & Juhlin, C. C. Comprehensive gene expression analysis in papillary thyroid carcinoma reveals a transcriptional profile associated with reduced radioiodine avidity. Endocr. Pathol. 36, 4 (2025).","journal-title":"Endocr. Pathol."},{"key":"1271_CR68","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/nrendo.2011.142","volume":"7","author":"YE Nikiforov","year":"2011","unstructured":"Nikiforov, Y. E. & Nikiforova, M. N. Molecular genetics and diagnosis of thyroid cancer. Nat. Rev. Endocrinol. 7, 569\u2013580 (2011).","journal-title":"Nat. Rev. Endocrinol."},{"key":"1271_CR69","doi-asserted-by":"publisher","first-page":"S34","DOI":"10.1038\/modpathol.2010.167","volume":"24","author":"YE Nikiforov","year":"2011","unstructured":"Nikiforov, Y. E. Molecular analysis of thyroid tumors. Mod. Pathol. 24, S34\u2013S43 (2011).","journal-title":"Mod. Pathol."},{"key":"1271_CR70","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1056\/NEJMra1501993","volume":"375","author":"JA Fagin","year":"2016","unstructured":"Fagin, J. A. & Wells, S. A. Biologic and clinical perspectives on thyroid cancer. N. Engl. J. Med. 375, 1054\u20131067 (2016).","journal-title":"N. Engl. J. Med."},{"key":"1271_CR71","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.cell.2014.09.050","volume":"159","author":"N Agrawal","year":"2014","unstructured":"Agrawal, N. et al. Integrated genomic characterization of papillary thyroid carcinoma. Cell 159, 676\u2013690 (2014).","journal-title":"Cell"},{"key":"1271_CR72","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41574-023-00920-6","volume":"20","author":"I Landa","year":"2024","unstructured":"Landa, I. & Cabanillas, M. E. Genomic alterations in thyroid cancer: biological and clinical insights. Nat. Rev. Endocrinol. 20, 93\u2013110 (2024).","journal-title":"Nat. Rev. Endocrinol."},{"key":"1271_CR73","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1172\/JCI85271","volume":"126","author":"I Landa","year":"2016","unstructured":"Landa, I. et al. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J. Clin. Investig. 126, 1052\u20131066 (2016).","journal-title":"J. Clin. Investig."},{"key":"1271_CR74","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1210\/clinem\/dgae532","volume":"110","author":"JR Wang","year":"2025","unstructured":"Wang, J. R. et al. The association between thyroid differentiation score and survival outcomes in papillary thyroid carcinoma. J. Clin. Endocrinol. Metab. 110, 356\u2013363 (2025).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1271_CR75","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1038\/s41379-020-00724-3","volume":"34","author":"JM Dolezal","year":"2021","unstructured":"Dolezal, J. M. et al. Deep learning prediction of BRAF\u2013RAS gene expression signature identifies noninvasive follicular thyroid neoplasms with papillary-like nuclear features. Mod. Pathol. 34, 862\u2013874 (2021).","journal-title":"Mod. Pathol."},{"key":"1271_CR76","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1002\/path.6456","volume":"267","author":"SL Asa","year":"2025","unstructured":"Asa, S. L. et al. Revisionist history uncovers a simplified molecular-based classification of differentiated thyroid cancer. J. Pathol. 267, 130\u2013141 (2025).","journal-title":"J. Pathol."},{"key":"1271_CR77","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1001","volume":"12","author":"C Montero-Conde","year":"2022","unstructured":"Montero-Conde, C. et al. Comprehensive molecular analysis of immortalization hallmarks in thyroid cancer reveals new prognostic markers. Clin. Transl. Med. 12, e1001 (2022).","journal-title":"Clin. Transl. Med."},{"key":"1271_CR78","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1093\/hmg\/ddu749","volume":"24","author":"JW Kunstman","year":"2015","unstructured":"Kunstman, J. W. et al. Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing. Hum. Mol. Genet. 24, 2318\u20132329 (2015).","journal-title":"Hum. Mol. Genet."},{"key":"1271_CR79","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1158\/1078-0432.CCR-18-0373","volume":"24","author":"N Pozdeyev","year":"2018","unstructured":"Pozdeyev, N. et al. Genetic analysis of 779 advanced differentiated and anaplastic thyroid cancers. Clin. Cancer Res. 24, 3059\u20133068 (2018).","journal-title":"Clin. Cancer Res."},{"key":"1271_CR80","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1177\/1457496919850434","volume":"109","author":"CC Juhlin","year":"2020","unstructured":"Juhlin, C. C. A clinical overview of telomerase-associated aberrancies in follicular thyroid tumors as diagnostic and prognostic markers: tert alert!. Scand. J. Surg. 109, 187\u2013192 (2020).","journal-title":"Scand. J. Surg."},{"key":"1271_CR81","doi-asserted-by":"publisher","first-page":"18346","DOI":"10.18632\/oncotarget.7811","volume":"7","author":"L Jin","year":"2016","unstructured":"Jin, L. et al. BRAF and TERT promoter mutations in the aggressiveness of papillary thyroid carcinoma: a study of 653 patients. Oncotarget 7, 18346\u201318355 (2016).","journal-title":"Oncotarget"},{"key":"1271_CR82","doi-asserted-by":"publisher","first-page":"E1130","DOI":"10.1210\/jc.2013-4048","volume":"99","author":"X Liu","year":"2014","unstructured":"Liu, X. et al. TERT promoter mutations and their association with BRAFV600E mutation and aggressive clinicopathological characteristics of thyroid cancer. J. Clin. Endocrinol. Metab. 99, E1130\u2013E1136 (2014).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1271_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.coemr.2023.100460","volume":"30","author":"I Landa","year":"2023","unstructured":"Landa, I. InTERTwined: how TERT promoter mutations impact BRAFV600E-driven thyroid cancers. Curr. Opin. Endocr. Metab. Res. 30, 100460 (2023).","journal-title":"Curr. Opin. Endocr. Metab. Res."},{"key":"1271_CR84","first-page":"2763","volume":"15","author":"AC Insilla","year":"2018","unstructured":"Insilla, A. C. et al. TERT promoter mutations and their correlation with BRAF and RAS mutations in a consecutive cohort of 145 thyroid cancer cases. Oncol. Lett. 15, 2763\u20132770 (2018).","journal-title":"Oncol. Lett."},{"key":"1271_CR85","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-75087-9","volume":"14","author":"G Tan","year":"2024","unstructured":"Tan, G. et al. TERT promoter mutations contribute to adverse clinical outcomes and poor prognosis in radioiodine refractory differentiated thyroid cancer. Sci. Rep. 14, 23719 (2024).","journal-title":"Sci. Rep."},{"key":"1271_CR86","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2024.05.058","volume":"177","author":"E Novis","year":"2025","unstructured":"Novis, E. et al. Oncogenic mutations in the TP53 and PI-3 kinase\/AKT pathway are independent predictors of survival for advanced thyroid cancer: analysis from the Molecular Screening and Therapeutics (MoST) program. Surgery 177, 108858 (2025).","journal-title":"Surgery"},{"key":"1271_CR87","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.3390\/ijms26031035","volume":"26","author":"K Lacka","year":"2025","unstructured":"Lacka, K. et al. Rationale for testing TP53 mutations in thyroid cancer-original data and meta-analysis. Int. J. Mol. Sci. 26, 1035 (2025).","journal-title":"Int. J. Mol. Sci."},{"key":"1271_CR88","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1038\/s41379-020-0458-7","volume":"33","author":"RD Chernock","year":"2020","unstructured":"Chernock, R. D. et al. Poorly differentiated thyroid carcinoma of childhood and adolescence: a distinct entity characterized by DICER1 mutations. Mod. Pathol. 33, 1264\u20131274 (2020).","journal-title":"Mod. Pathol."},{"key":"1271_CR89","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1210\/clinem\/dgab025","volume":"106","author":"A-S Chong","year":"2021","unstructured":"Chong, A.-S. et al. Prevalence and spectrum of DICER1 mutations in adult-onset thyroid nodules with indeterminate cytology. J. Clin. Endocrinol. Metab. 106, 968\u2013977 (2021).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1271_CR90","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1210\/clinem\/dgae034","volume":"109","author":"V Condello","year":"2024","unstructured":"Condello, V. et al. Prevalence, molecular landscape, and clinical impact of DICER1 and DGCR8 mutated follicular-patterned thyroid nodules. J. Clin. Endocrinol. Metab. 109, 1733\u20131744 (2024).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1271_CR91","doi-asserted-by":"publisher","DOI":"10.1530\/ETJ-24-0298","volume":"13","author":"V Condello","year":"2024","unstructured":"Condello, V. & Juhlin, C. C. MicroRNA regulator gene mutations in thyroid follicular nodular disease and thyroid cancer: does it all come down to timing? Eur. Thyroid. J. 13, e240298 (2024).","journal-title":"Eur. Thyroid. J."},{"key":"1271_CR92","doi-asserted-by":"publisher","first-page":"3265","DOI":"10.1210\/clinem\/dgab471","volume":"106","author":"JO Paulsson","year":"2021","unstructured":"Paulsson, J. O. et al. Whole-genome sequencing of follicular thyroid carcinomas reveal recurrent mutations in microRNA processing subunit DGCR8. J. Clin. Endocrinol. Metab. 106, 3265\u20133282 (2021).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1271_CR93","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1172\/JCI130206","volume":"130","author":"B Rivera","year":"2020","unstructured":"Rivera, B. et al. DGCR8 microprocessor defect characterizes familial multinodular goiter with schwannomatosis. J. Clin. Invest. 130, 1479\u20131490 (2020).","journal-title":"J. Clin. Invest."},{"key":"1271_CR94","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1158\/2159-8290.CD-20-0735","volume":"11","author":"M Saqcena","year":"2021","unstructured":"Saqcena, M. et al. SWI\/SNF complex mutations promote thyroid tumor progression and insensitivity to redifferentiation therapies. Cancer Discov. 11, 1158\u20131175 (2021).","journal-title":"Cancer Discov."},{"key":"1271_CR95","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1158\/1078-0432.CCR-22-2882","volume":"29","author":"L Boucai","year":"2023","unstructured":"Boucai, L. et al. Genomic and transcriptomic characteristics of metastatic thyroid cancers with exceptional responses to radioactive iodine therapy. Clin. Cancer Res. 29, 1620\u20131630 (2023).","journal-title":"Clin. Cancer Res."},{"key":"1271_CR96","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1158\/2159-8290.CD-21-0010","volume":"11","author":"J Massagu\u00e9","year":"2021","unstructured":"Massagu\u00e9, J. & Ganesh, K. Metastasis-initiating cells and ecosystems. Cancer Discov. 11, 971\u2013994 (2021).","journal-title":"Cancer Discov."},{"key":"1271_CR97","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.cell.2022.01.003","volume":"185","author":"B Nguyen","year":"2022","unstructured":"Nguyen, B. et al. Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. Cell 185, 563\u2013575 (2022).","journal-title":"Cell"},{"key":"1271_CR98","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1210\/jc.2005-1534","volume":"91","author":"RJ Robbins","year":"2006","unstructured":"Robbins, R. J. et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-d-glucose-positron emission tomography scanning. J. Clin. Endocrinol. Metab. 91, 498\u2013505 (2006).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1271_CR99","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1177\/1758834014548188","volume":"6","author":"F Worden","year":"2014","unstructured":"Worden, F. Treatment strategies for radioactive iodine-refractory differentiated thyroid cancer. Ther. Adv. Med. Oncol. 6, 267\u2013279 (2014).","journal-title":"Ther. Adv. Med. Oncol."},{"key":"1271_CR100","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1159\/000502229","volume":"8","author":"L Fugazzola","year":"2019","unstructured":"Fugazzola, L. et al. 2019 European Thyroid Association guidelines for the treatment and follow-up of advanced radioiodine-refractory thyroid cancer. Eur. Thyroid J. 8, 227\u2013245 (2019).","journal-title":"Eur. Thyroid J."},{"key":"1271_CR101","first-page":"2493","volume":"83","author":"F Arturi","year":"1998","unstructured":"Arturi, F. et al. Iodide symporter gene expression in human thyroid tumors. J. Clin. Endocrinol. Metab. 83, 2493\u20132496 (1998).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1271_CR102","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.3390\/diagnostics14242817","volume":"14","author":"M Buzejic","year":"2024","unstructured":"Buzejic, M. et al. Prognostic factors for cancer-specific survival and disease-free interval in 130 patients with follicular thyroid carcinoma: single institution experience. Diagnostics 14, 2817 (2024).","journal-title":"Diagnostics"},{"key":"1271_CR103","doi-asserted-by":"publisher","first-page":"3144","DOI":"10.1210\/clinem\/dgac448","volume":"107","author":"X Wang","year":"2022","unstructured":"Wang, X., Zheng, X., Zhu, J., Li, Z. & Wei, T. Radioactive iodine therapy does not improve cancer-specific survival in h\u00fcrthle cell carcinoma of the thyroid. J. Clin. Endocrinol. Metab. 107, 3144\u20133151 (2022).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1271_CR104","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1007\/s00405-023-07832-1","volume":"280","author":"A Abiri","year":"2023","unstructured":"Abiri, A. et al. A comparative analysis of treatment efficacy in intermediate-risk thyroid cancer. Eur. Arch. Otorhinolaryngol. 280, 2525\u20132533 (2023).","journal-title":"Eur. Arch. Otorhinolaryngol."},{"key":"1271_CR105","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1001\/jamaoncol.2019.6851","volume":"6","author":"AS Ho","year":"2020","unstructured":"Ho, A. S. et al. Incidence and mortality risk spectrum across aggressive variants of papillary thyroid carcinoma. JAMA Oncol. 6, 706\u2013713 (2020).","journal-title":"JAMA Oncol."},{"key":"1271_CR106","doi-asserted-by":"publisher","first-page":"1665545","DOI":"10.3389\/fendo.2025.1665545","volume":"16","author":"B Wang","year":"2025","unstructured":"Wang, B., Cen, X.-X., Zhang, B.-R. & Zhang, W. The effect of BRAFV600E mutation on radioiodine therapy in patients with papillary thyroid carcinoma: a meta-analysis and systematic review. Front. Endocrinol. 16, 1665545 (2025).","journal-title":"Front. Endocrinol."},{"key":"1271_CR107","doi-asserted-by":"publisher","first-page":"177","DOI":"10.2967\/jnumed.119.227652","volume":"61","author":"J Liu","year":"2020","unstructured":"Liu, J. et al. The genetic duet of BRAFV600E and TERT promoter mutations robustly predicts loss of radioiodine avidity in recurrent papillary thyroid cancer. J. Nucl. Med. 61, 177\u2013182 (2020).","journal-title":"J. Nucl. Med."},{"key":"1271_CR108","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1007\/s12149-022-01806-9","volume":"36","author":"B Hertz","year":"2022","unstructured":"Hertz, B., Watabe, T. & Baum, R. P. Celebrating 80 years anniversary of radioiodine for use in thyroid cancer and perspectives for theranostics. Ann. Nucl. Med. 36, 1007\u20131009 (2022).","journal-title":"Ann. Nucl. Med."},{"key":"1271_CR109","first-page":"1999","volume":"76","author":"M Tubiana","year":"1968","unstructured":"Tubiana, M., Perez, R., Parmentier, C. & Monnier, J. P. [The survival of patients with thyroid cancers treated with radioactive iodine. Apropos of 147 cases followed up for more than 5 years]. Presse Med. 76, 1999\u20132002 (1968).","journal-title":"Presse Med."},{"key":"1271_CR110","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/0002-9343(81)90573-8","volume":"70","author":"EL Mazzaferri","year":"1981","unstructured":"Mazzaferri, E. L. & Young, R. L. Papillary thyroid carcinoma: a 10 year follow-up report of the impact of therapy in 576 patients. Am. J. Med. 70, 511\u2013518 (1981).","journal-title":"Am. J. Med."},{"key":"1271_CR111","first-page":"743","volume":"24","author":"JC Sisson","year":"1983","unstructured":"Sisson, J. C. Applying the radioactive eraser: I-131 to ablate normal thyroid tissue in patients from whom thyroid cancer has been resected. J. Nucl. Med. 24, 743\u2013745 (1983).","journal-title":"J. Nucl. Med."},{"key":"1271_CR112","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1007\/s00268-002-6612-1","volume":"26","author":"ID Hay","year":"2002","unstructured":"Hay, I. D. et al. Papillary thyroid carcinoma managed at the mayo clinic during six decades (1940\u20131999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J. Surg. 26, 879\u2013885 (2002).","journal-title":"World J. Surg."},{"key":"1271_CR113","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1093\/annonc\/mdz400","volume":"30","author":"S Filetti","year":"2019","unstructured":"Filetti, S. et al. Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 30, 1856\u20131883 (2019).","journal-title":"Ann. Oncol."},{"key":"1271_CR114","doi-asserted-by":"crossref","first-page":"15N","DOI":"10.2967\/jnumed.121.262402","volume":"63","author":"AM Avram","year":"2022","unstructured":"Avram, A. M. et al. SNMMI procedure standard\/EANM practice guideline for nuclear medicine evaluation and therapy of differentiated thyroid cancer: abbreviated version. J. Nucl. Med. 63, 15N\u201335N (2022).","journal-title":"J. Nucl. Med."},{"key":"1271_CR115","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1111\/cen.13306","volume":"86","author":"P Santhanam","year":"2017","unstructured":"Santhanam, P., Taieb, D., Solnes, L., Marashdeh, W. & Ladenson, P. W. Utility of I-124 PET\/CT in identifying radioiodine avid lesions in differentiated thyroid cancer: a systematic review and meta-analysis. Clin. Endocrinol. 86, 645\u2013651 (2017).","journal-title":"Clin. Endocrinol."},{"key":"1271_CR116","first-page":"910","volume":"28","author":"H Joensuu","year":"1987","unstructured":"Joensuu, H. & Ahonen, A. Imaging of metastases of thyroid carcinoma with fluorine-18 fluorodeoxyglucose. J. Nucl. Med. 28, 910\u2013914 (1987).","journal-title":"J. Nucl. Med."},{"key":"1271_CR117","first-page":"1468","volume":"37","author":"U Feine","year":"1996","unstructured":"Feine, U. et al. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J. Nucl. Med. 37, 1468\u20131472 (1996).","journal-title":"J. Nucl. Med."},{"key":"1271_CR118","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-22656-4","volume":"8","author":"M Liu","year":"2018","unstructured":"Liu, M. et al. Predicting 131I-avidity of metastases from differentiated thyroid cancer using 18F-FDG PET\/CT in postoperative patients with elevated thyroglobulin. Sci. Rep. 8, 4352 (2018).","journal-title":"Sci. Rep."},{"key":"1271_CR119","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1097\/RLU.0000000000000498","volume":"39","author":"K Yang","year":"2014","unstructured":"Yang, K. et al. BRAFV600E mutation associated with non-radioiodine-avid status in distant metastatic papillary thyroid carcinoma. Clin. Nucl. Med. 39, 675\u2013679 (2014).","journal-title":"Clin. Nucl. Med."},{"key":"1271_CR120","doi-asserted-by":"publisher","first-page":"6373","DOI":"10.1210\/jc.2005-0987","volume":"90","author":"M Xing","year":"2005","unstructured":"Xing, M. et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J. Clin. Endocrinol. Metab. 90, 6373\u20136379 (2005).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1271_CR121","doi-asserted-by":"publisher","first-page":"E829","DOI":"10.1210\/jc.2012-3933","volume":"98","author":"MM Sabra","year":"2013","unstructured":"Sabra, M. M. et al. Clinical outcomes and molecular profile of differentiated thyroid cancers with radioiodine-avid distant metastases. J. Clin. Endocrinol. Metab. 98, E829\u2013E836 (2013).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1271_CR122","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41388-023-02889-y","volume":"43","author":"H Lasolle","year":"2024","unstructured":"Lasolle, H. et al. Dual targeting of MAPK and PI3K pathways unlocks redifferentiation of Braf-mutated thyroid cancer organoids. Oncogene 43, 155\u2013170 (2024).","journal-title":"Oncogene"},{"key":"1271_CR123","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1530\/EJE-09-0702","volume":"161","author":"H Hoftijzer","year":"2009","unstructured":"Hoftijzer, H. et al. Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur. J. Endocrinol. 161, 923\u2013931 (2009).","journal-title":"Eur. J. Endocrinol."},{"key":"1271_CR124","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1007\/BF03346457","volume":"32","author":"CA Fern\u00e1ndez","year":"2009","unstructured":"Fern\u00e1ndez, C. A. et al. Effectiveness of retinoic acid treatment for redifferentiation of thyroid cancer in relation to recovery of radioiodine uptake. J. Endocrinol. Invest. 32, 228\u2013233 (2009).","journal-title":"J. Endocrinol. Invest."},{"key":"1271_CR125","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/cen.13806","volume":"89","author":"H Luo","year":"2018","unstructured":"Luo, H. et al. The effect of lithium on the progression-free and overall survival in patients with metastatic differentiated thyroid cancer undergoing radioactive iodine therapy. Clin. Endocrinol. 89, 481\u2013488 (2018).","journal-title":"Clin. Endocrinol."},{"key":"1271_CR126","doi-asserted-by":"publisher","first-page":"R113","DOI":"10.1530\/ERC-19-0491","volume":"27","author":"C Buffet","year":"2020","unstructured":"Buffet, C. et al. Redifferentiation of radioiodine-refractory thyroid cancers. Endocr. Relat. Cancer 27, R113\u2013R132 (2020).","journal-title":"Endocr. Relat. Cancer"},{"key":"1271_CR127","doi-asserted-by":"publisher","first-page":"4194","DOI":"10.1158\/1078-0432.CCR-22-0437","volume":"28","author":"M Weber","year":"2022","unstructured":"Weber, M. et al. Enhancing radioiodine incorporation into radioiodine-refractory thyroid cancer with MAPK Inhibition (ERRITI): a single-center prospective two-arm study. Clin. Cancer Res. 28, 4194\u20134202 (2022).","journal-title":"Clin. Cancer Res."},{"key":"1271_CR128","first-page":"1124","volume":"33","author":"S Leboulleux","year":"2023","unstructured":"Leboulleux, S. et al. MERAIODE: a phase II redifferentiation trial with trametinib and 131I in metastatic radioactive iodine refractory RAS mutated differentiated thyroid cancer. Thyroid 33, 1124\u20131129 (2023).","journal-title":"Thyroid"},{"key":"1271_CR129","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1089\/thy.2021.0524","volume":"32","author":"L Groussin","year":"2022","unstructured":"Groussin, L. et al. Redifferentiating effect of larotrectinib in NTRK-rearranged advanced radioactive-iodine refractory thyroid cancer. Thyroid 32, 594\u2013598 (2022).","journal-title":"Thyroid"},{"key":"1271_CR130","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1089\/thy.2021.0565","volume":"32","author":"V Tchekmedyian","year":"2022","unstructured":"Tchekmedyian, V. et al. Enhancing radioiodine incorporation in BRAF-mutant, radioiodine-refractory thyroid cancers with vemurafenib and the anti-ErbB3 monoclonal antibody CDX-3379: results of a pilot clinical trial. Thyroid 32, 273\u2013282 (2022).","journal-title":"Thyroid"},{"key":"1271_CR131","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1089\/thy.2023.0228","volume":"33","author":"D Balakirouchenane","year":"2023","unstructured":"Balakirouchenane, D. et al. Pharmacokinetics\/pharmacodynamics of dabrafenib and trametinib for redifferentiation and treatment of radioactive iodine-resistant mutated advanced differentiated thyroid cancer. Thyroid 33, 1327\u20131338 (2023).","journal-title":"Thyroid"},{"key":"1271_CR132","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s12020-026-04588-6","volume":"91","author":"K Shi","year":"2026","unstructured":"Shi, K. et al. BRAF\/MEK inhibitors for redifferentiation in patients with radioiodine refractory thyroid cancer: a systematic review and meta-analysis. Endocrine 91, 121 (2026).","journal-title":"Endocrine"},{"key":"1271_CR133","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/S2213-8587(25)00064-6","volume":"13","author":"S Leboulleux","year":"2025","unstructured":"Leboulleux, S. et al. Redifferentiation therapy in unresectable or metastatic radioactive iodine refractory thyroid cancer: an international thyroid oncology group statement. Lancet Diabetes Endocrinol. 13, 516\u2013527 (2025).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1271_CR134","doi-asserted-by":"publisher","first-page":"21458","DOI":"10.1074\/jbc.M100561200","volume":"276","author":"C Riedel","year":"2001","unstructured":"Riedel, C., Levy, O. & Carrasco, N. Post-transcriptional regulation of the sodium\/iodide symporter by thyrotropin. J. Biol. Chem. 276, 21458\u201321463 (2001).","journal-title":"J. Biol. Chem."},{"key":"1271_CR135","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1210\/er.2012-1036","volume":"35","author":"C Portulano","year":"2014","unstructured":"Portulano, C., Paroder-Belenitsky, M. & Carrasco, N. The Na+\/I\u2212 symporter (NIS): mechanism and medical impact. Endocr. Rev. 35, 106\u2013149 (2014).","journal-title":"Endocr. Rev."},{"key":"1271_CR136","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1677\/joe.0.1670125","volume":"167","author":"T Kogai","year":"2000","unstructured":"Kogai, T. et al. Induction of follicle formation in long-term cultured normal human thyroid cells treated with thyrotropin stimulates iodide uptake but not sodium\/iodide symporter messenger RNA and protein expression. J. Endocrinol. 167, 125\u2013135 (2000).","journal-title":"J. Endocrinol."},{"key":"1271_CR137","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1210\/jc.2002-021544","volume":"88","author":"IL Wapnir","year":"2003","unstructured":"Wapnir, I. L. et al. Immunohistochemical profile of the sodium\/iodide symporter in thyroid, breast, and other carcinomas using high density tissue microarrays and conventional sections. J. Clin. Endocrinol. Metab. 88, 1880\u20131888 (2003).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1271_CR138","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1259\/0007-1285-50-599-799","volume":"50","author":"CJ Edmonds","year":"1977","unstructured":"Edmonds, C. J., Hayes, S., Kermode, J. C. & Thompson, B. D. Measurement of serum TSH and thyroid hormones in the management of treatment of thyroid carcinoma with radioiodine. Br. J. Radiol. 50, 799\u2013807 (1977).","journal-title":"Br. J. Radiol."},{"key":"1271_CR139","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","volume":"26","author":"BR Haugen","year":"2016","unstructured":"Haugen, B. R. et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26, 1\u2013133 (2016).","journal-title":"Thyroid"},{"key":"1271_CR140","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1007\/s00259-008-0883-1","volume":"35","author":"M Luster","year":"2008","unstructured":"Luster, M. et al. Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur. J. Nucl. Med. Mol. Imaging 35, 1941\u20131959 (2008).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1271_CR141","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.601960","volume":"12","author":"W Zheng","year":"2021","unstructured":"Zheng, W. et al. The influences of TSH stimulation level, stimulated Tg level and Tg\/TSH ratio on the therapeutic effect of 131I treatment in DTC patients. Front. Endocrinol. 12, 601960 (2021).","journal-title":"Front. Endocrinol."},{"key":"1271_CR142","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1007\/s00259-015-3223-2","volume":"43","author":"A Vrachimis","year":"2016","unstructured":"Vrachimis, A., Riemann, B., M\u00e4der, U., Reiners, C. & Verburg, F. A. Endogenous TSH levels at the time of 131I ablation do not influence ablation success, recurrence-free survival or differentiated thyroid cancer-related mortality. Eur. J. Nucl. Med. Mol. Imaging 43, 224\u2013231 (2016).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1271_CR143","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.3390\/cancers15092510","volume":"15","author":"L Giovanella","year":"2023","unstructured":"Giovanella, L., Garo, M. L., Campenn\u00ed, A., Petranovi\u0107 Ov\u010dari\u010dek, P. & G\u00f6rges, R. Thyroid hormone withdrawal versus recombinant human TSH as preparation for I-131 therapy in patients with metastatic thyroid cancer: a systematic review and meta-analysis. Cancers 15, 2510 (2023).","journal-title":"Cancers"},{"key":"1271_CR144","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/ncpendmet0594","volume":"3","author":"M Schlumberger","year":"2007","unstructured":"Schlumberger, M., Ricard, M., De Pouvourville, G. & Pacini, F. How the availability of recombinant human TSH has changed the management of patients who have thyroid cancer. Nat. Clin. Pract. Endocrinol. Metab. 3, 641\u2013650 (2007).","journal-title":"Nat. Clin. Pract. Endocrinol. Metab."},{"key":"1271_CR145","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvaf050","volume":"9","author":"A Kotwal","year":"2025","unstructured":"Kotwal, A. et al. Recombinant TSH performs as well as thyroid hormone withdrawal for iodine-131 therapy with dosimetry for thyroid cancer. J. Endocr. Soc. 9, bvaf050 (2025).","journal-title":"J. Endocr. Soc."},{"key":"1271_CR146","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/S0021-9258(18)57335-X","volume":"174","author":"J Wolff","year":"1948","unstructured":"Wolff, J. & Chaikoff, I. L. Plasma inorganic iodide as a homeostatic regulator of thyroid function. J. Biol. Chem. 174, 555\u2013564 (1948).","journal-title":"J. Biol. Chem."},{"key":"1271_CR147","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1111\/cen.14751","volume":"97","author":"G Herbert","year":"2022","unstructured":"Herbert, G. et al. Impact of low iodine diets on ablation success in differentiated thyroid cancer: a mixed-methods systematic review and meta-analysis. Clin. Endocrinol. 97, 702\u2013729 (2022).","journal-title":"Clin. Endocrinol."},{"key":"1271_CR148","doi-asserted-by":"publisher","first-page":"T121","DOI":"10.1530\/ERC-21-0037","volume":"28","author":"P Borges De Souza","year":"2021","unstructured":"Borges De Souza, P. & McCabe, C. J. Radioiodine treatment: an historical and future perspective. Endocr. Relat. Cancer 28, T121\u2013T124 (2021).","journal-title":"Endocr. Relat. Cancer"},{"key":"1271_CR149","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/133201a0","volume":"133","author":"F Joliot","year":"1934","unstructured":"Joliot, F. & Curie, I. Artificial production of a new kind of radio-element. Nature 133, 201\u2013202 (1934).","journal-title":"Nature"},{"key":"1271_CR150","doi-asserted-by":"publisher","first-page":"e146","DOI":"10.1016\/S1470-2045(19)30821-6","volume":"21","author":"K Herrmann","year":"2020","unstructured":"Herrmann, K. et al. Radiotheranostics: a roadmap for future development. Lancet Oncol. 21, e146\u2013e156 (2020).","journal-title":"Lancet Oncol."},{"key":"1271_CR151","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06991738 (2025)."},{"key":"1271_CR152","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06639191 (2024)."},{"key":"1271_CR153","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1158\/1078-0432.CCR-23-2043","volume":"30","author":"ML Read","year":"2024","unstructured":"Read, M. L. et al. Combined vorinostat and chloroquine inhibit sodium\u2013iodide symporter endocytosis and enhance radionuclide uptake in vivo. Clin. Cancer Res. 30, 1352\u20131366 (2024).","journal-title":"Clin. Cancer Res."},{"key":"1271_CR154","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1006239","volume":"12","author":"S-K Yoo","year":"2016","unstructured":"Yoo, S.-K. et al. Comprehensive analysis of the transcriptional and mutational landscape of follicular and papillary thyroid cancers. PLoS Genet. 12, e1006239 (2016).","journal-title":"PLoS Genet."}],"container-title":["Nature Reviews Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41574-026-01271-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41574-026-01271-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41574-026-01271-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T12:02:18Z","timestamp":1788955338000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41574-026-01271-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":154,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1271"],"URL":"https:\/\/doi.org\/10.1038\/s41574-026-01271-8","relation":{},"ISSN":["1759-5029","1759-5037"],"issn-type":[{"value":"1759-5029","type":"print"},{"value":"1759-5037","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]},"assertion":[{"value":"29 May 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}